Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty

COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY.

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02185924

Enrollment

Registered

2014-07-10

Start date

2009-01-31

Completion date

2014-02-28

Last updated

2014-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POSTOPERATIVE ANALGESIA FOR TKA PARECOXIB/CFB

Keywords

PARECOXIB, CONTINUOUS FEMORAL BLOCK

Brief summary

Combination of continuous femoral block with parEcoxib vs placebo. Investigation of morphine consumption, opioid sparing effects, VAS pain scores, haemodynamics, Anxierty scores, transfusion requirements , Range of motion and rehabilitation parameters between two groups

Interventions

DRUGParecoxib

DRUGCONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%

DRUGN/S 0.9%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* PATIENTS ASA I-II UNDERGOING TOTAL KNEE ATRTHROPLASTY

Design outcomes

Primary

Measure	Time frame
MORPHINE CONSUMPTION WITH PCA BETWEEN TWO GROUPS	36/h POSTOPERATIVELY
VAS PAIN SCORES BETWEEN TWO GROUPS	36/h POSTOPERATIVELY
HAEMODYNAMIC PARAMETERS BETWEEN TWO GROUPS	During perioperative period

Secondary

Measure	Time frame	Description
ANXIETY LEVELS	36 HOURS POSTOPERATIVELY	ANXIETY SCORES WERE QUANTIFIED USING THE SPIELBERG INVENTORY

Other

Measure	Time frame
RANGE OF MOTION, TRANSFUSION REQUIREMENTS, VAS SCORES POSTOPERATIVELY	AFTER 36 HOURS POSTOPERATIVELY
MODIFIED BROMAGE SCALE	36/h POSTOPEPATIVELY

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026